Idiopathic Vitritis after Boston Type 1 Keratoprosthesis Implantation: Incidence, Risk Factors and Outcomes in a Multicentric Cohort.


Journal

Ocular immunology and inflammation
ISSN: 1744-5078
Titre abrégé: Ocul Immunol Inflamm
Pays: England
ID NLM: 9312169

Informations de publication

Date de publication:
19 May 2022
Historique:
pubmed: 16 10 2020
medline: 2 9 2022
entrez: 15 10 2020
Statut: ppublish

Résumé

To determine incidence, risks factors for, and outcomes of idiopathic vitritis (IV) after Boston type 1 keratoprosthesis (KPro) implantation. Retrospective, consecutive case series. Risk factors were analyzed between IV group and No IV group. IV occurred in 32/350 procedures (9.1%), for an average incidence of 0.02 cases per procedure-year. Presumed infectious keratitis was the only risk factor identified (HR = 7.65) Corneal necrosis and retinal detachment occurred significantly more frequently in IV group (all IV is associated with infectious keratitis, indicating that the vitritis may not be a sterile process. The increased incidence of subsequent complications leads to significantly decreased visual acuity and KPro retention in affected eyes.

Identifiants

pubmed: 33054501
doi: 10.1080/09273948.2020.1826541
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

769-775

Auteurs

Clemence Bonnet (C)

Stein Eye Institute, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Ophthalmology Department, AP-HP, Cochin Hospital, Paris University, Paris, France.

Ismael Chehaibou (I)

Stein Eye Institute, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Ophthalmology Department, Université De Paris, AP-HP, Hôpital Lariboisière, Paris, France.

Reza Ghaffari (R)

Stein Eye Institute, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.

Nicholas J Jackson (NJ)

Department of Medicine Statistics Core, University of California, Los Angeles, Los Angeles, California, USA.

Cristina Bostan (C)

Department of Ophthalmology, Centre Hospitalier De l'Université De Montréal, Montréal, Québec, Canada.

Jean-Pierre Hubschman (JP)

Stein Eye Institute, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.

Mona Harissi-Dagher (M)

Department of Ophthalmology, Centre Hospitalier De l'Université De Montréal, Montréal, Québec, Canada.

Anthony J Aldave (AJ)

Stein Eye Institute, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH